Veracyte touts Percepta clinical trial results

By staff writers

August 6, 2020 -- Veracyte is highlighting clinical trial results published August 3 in Chest that show its Percepta classifier can reduce the need for subsequent invasive procedures for lung cancer diagnosis by better classifying low-risk patients after inconclusive bronchoscopy.

A team led by Dr. Hans Lee of Johns Hopkins University in Baltimore conducted a study that included 213 patients with low or intermediate risk of malignancy and a nondiagnostic bronchoscopy from 35 academic and community centers in the U.S.

The study showed that Percepta down-classified the risk of malignancy by 34.3% in 67 patients scheduled for a subsequent invasive procedures; physicians changed management plans for 73.9% of these patients (from invasive procedure to surveillance), and 61% were able to avoid further procedures for up to a year after initial evaluation, Veracyte said.

In other Veracyte news, the company announced a public offering of 6 million shares of common stock at $30 per share. Proceeds of the offering are expected to be $180 million; it will close on August 7. Veracyte plans to use the funds for working capital but also to acquire or invest in complementary businesses or technologies, it said.

Veracyte, CareDx partner for transplant rejection testing
CareDx will become the exclusive commercialization partner for solid organ transplant rejection tests that run on Veracyte's nCounter Flex Analysis System...
Veracyte licenses gene signature for idiopathic pulmonary fibrosis
Veracyte has licensed exclusive rights to a 52-gene signature for idiopathic pulmonary fibrosis from Yale University and plans to develop a blood test...
Veracyte licenses NanoString diagnostic platform in $50M deal
Veracyte is set to pay $50 million -- $40 million in cash and the rest in common stock -- for an exclusive global license to the NanoString...
Veracyte nasal swab test holds its own in lung cancer detection
Veracyte said the accuracy of its investigational nasal swab genomic classifying test rivals the clinical standard for lung nodule assessment and has...
Veracyte validates Afirma XA in thyroid cancer
Veracyte published data in Frontiers in Endocrinology on September 11 supporting the utility of its Afirma Expression Atlas (XA) test for identifying...

Copyright © 2020

Last Updated ls 8/6/2020 1:47:03 PM